DVAX Dynavax Technologies Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: DVAX

Price (delayed)

$13.7

Market cap

$1.77B

P/E Ratio

28.54

Dividend/share

N/A

EPS

$0.48

Enterprise value

$1.87B

Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company's commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. for prevention of ...

Highlights
Dynavax Technologies's equity has increased by 21% YoY and by 4.8% from the previous quarter
DVAX's gross margin is up by 6% QoQ and by 3.7% YoY
DVAX's price to earnings (P/E) is 105% higher than its last 4 quarters average of 13.9
DVAX's EPS has plunged by 82% YoY and by 45% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.dynavax.com
Peers: AGEN BIIB MRK GILD

Key stats

What are the main financial stats of DVAX
Market
Shares outstanding
129.26M
Market cap
$1.77B
Enterprise value
$1.87B
Valuations
Price to earnings (P/E)
28.54
Price to book (P/B)
2.92
Price to sales (P/S)
4.89
EV/EBIT
26.95
EV/EBITDA
24.56
EV/Sales
5.18
Earnings
Revenue
$361.18M
EBIT
$69.36M
EBITDA
$76.13M
Free cash flow
$118.78M
Per share
EPS
$0.48
Free cash flow per share
$0.92
Book value per share
$4.7
Revenue per share
$2.8
TBVPS
$7.53
Balance sheet
Total assets
$972.93M
Total liabilities
$368.02M
Debt
$253.1M
Equity
$604.92M
Working capital
$781.4M
Liquidity
Debt to equity
0.42
Current ratio
15.4
Quick ratio
14.14
Net debt/EBITDA
1.29
Margins
EBITDA margin
21.1%
Gross margin
67.1%
Net margin
16.9%
Operating margin
9.6%
Efficiency
Return on assets
6.3%
Return on equity
10.5%
Return on invested capital
7.4%
Return on capital employed
7.6%
Return on sales
19.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

DVAX stock price

How has the Dynavax Technologies stock price performed over time
Intraday
2.47%
1 week
1.63%
1 month
-5.26%
1 year
10.39%
YTD
28.76%
QTD
-7.24%

Financial performance

How have Dynavax Technologies's revenue and profit performed over time
Revenue
$361.18M
Gross profit
$242.21M
Operating income
$34.6M
Net income
$61.13M
Gross margin
67.1%
Net margin
16.9%
DVAX's operating income has dropped by 89% year-on-year and by 62% since the previous quarter
The net income has dropped by 81% year-on-year and by 45% since the previous quarter
The company's operating margin has shrunk by 77% YoY and by 52% QoQ
Dynavax Technologies's net margin has plunged by 62% YoY and by 30% from the previous quarter

Growth

What is Dynavax Technologies's growth rate over time

Valuation

What is Dynavax Technologies stock price valuation
DVAX P/E details
P/E
28.54
P/B
2.92
P/S
4.89
EV/EBIT
26.95
EV/EBITDA
24.56
EV/Sales
5.18
DVAX's price to earnings (P/E) is 105% higher than its last 4 quarters average of 13.9
DVAX's EPS has plunged by 82% YoY and by 45% from the previous quarter
DVAX's P/B is 77% below its 5-year quarterly average of 12.5 but 12% above its last 4 quarters average of 2.6
Dynavax Technologies's equity has increased by 21% YoY and by 4.8% from the previous quarter
The P/S is 59% less than the 5-year quarterly average of 11.9 but 53% more than the last 4 quarters average of 3.2
DVAX's revenue has dropped by 51% year-on-year and by 21% since the previous quarter

Efficiency

How efficient is Dynavax Technologies business performance
The ROE has plunged by 88% YoY and by 47% from the previous quarter
Dynavax Technologies's return on invested capital has shrunk by 87% YoY and by 45% QoQ
Dynavax Technologies's ROA has plunged by 80% YoY and by 44% from the previous quarter
DVAX's ROS has plunged by 58% YoY and by 26% from the previous quarter

Dividends

What is DVAX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for DVAX.

Financial health

How did Dynavax Technologies financials performed over time
Dynavax Technologies's total assets is 164% higher than its total liabilities
The company's total liabilities fell by 26% YoY but it rose by 2.4% QoQ
DVAX's quick ratio is down by 13% QoQ
Dynavax Technologies's debt is 58% less than its equity
Dynavax Technologies's equity has increased by 21% YoY and by 4.8% from the previous quarter
The debt to equity has contracted by 18% YoY and by 4.5% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.